Gravity Analytica

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

MYGN 10.30.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-13

Name of Upcoming Event:Guggenheim Inaugural Global Healthcare Conference

Date of Upcoming Event:2024-11-20

Name of Upcoming Event:6th Annual Wolfe Research Healthcare Conference

Full Press Release SEC Filings Our MYGN Tweets

About Gravity Analytica

Recent Filings

Management will also participate in two upcoming investor healthcare conferences

SALT LAKE CITY, Oct. 30, 2024 (GLOBE NEWSWIRE) --Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Thursday, November 7, 2024 at 4:30 pm ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2024.

A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website atinvestor.myriad.com. To participate in the live conference call via telephone, pleaseregister here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available atinvestor.myriad.comfollowing the call.

Q4 Investor ConferencesManagement will also be participating in the following investor healthcare conferences:

The Guggenheim Inaugural Global Healthcare Conference in a fireside chat featuring Paul J. Diaz, President and CEO, on Wednesday, November 13, 2024 at 3:30 pm ET.
The 6th Annual Wolfe Research Healthcare Conference in a fireside chat featuring Scott Leffler, Chief Financial Officer, and Sam Raha, Chief Operating Officer, on Wednesday, November 20, 2024 at 3:20 pm ET.

Live and archived webcasts of all presentations can be viewed atinvestor.myriad.com.

About Myriad GeneticsMyriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visitwww.myriad.com.

Investor ContactMatt Scalo(801) 584-3532IR@myriad.com

Media ContactGlenn Farrell(385) 318-3718PR@myriad.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com